Sign in

NCT07220278Recruiting

Ongoing Dynamic Choice to Address HIV Treatment Interruption in Malawi

Ongoing Dynamic Choice to Address HIV Treatment Interruption in Malawi (CHOICE)

Source: ClinicalTrials.gov · Last updated 18 Dec 2025

Brief summary (registry, in English)

Repeat and prolonged treatment interruption (TI) is common and the major threat to HIV epidemic control in eastern and southern Africa. The proposed project will test an innovative long-term dynamic choice intervention for ART clients experiencing TI in Malawi. Findings will provide essential information on how to improve sustained retention among TI client, a critical step to curbing the HIV epidemic. TI clients need long-term, responsive interventions. There are no one-size fits all intervention to support long-term care for TI clients because clients experience vastly different and changing barriers to care. While health facilities do have limited capacity for adding new services, existing services can be packaged differently to meet clients' needs. Long-term, dynamic choice of services is one way to provide responsive services and promotes client ownership over care. The investigators propose to give TI clients long-term, dynamic choice of what services they receive and how they receive it (drawing from key building blocks of DSD). Long-term, dynamic choice puts clients in the driver's seat and may be the best practical strategy to provide long-term and responsive TI interventions that are tailored to clients' evolving life circumstances. Dynamic choice is frequently used for HIV prevention and family planning products, whereby clients select the type of health product that works best for them (i.e., condoms, injectables, etc.). Choice of these services is strongly associated with improved outcomes. The goal of this clinical trial is to determine if CHOICE can improve outcomes in TI clients, compared to standard of care (SOC). Participants will be randomly assigned to either the CHOICE or SOC group, and follow them for 12 months. The primary outcome will be viral suppression at 12 months.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
800 (estimated)
First submitted
15 Oct 2025
Start date
17 Nov 2025
Primary completion date
1 Jul 2028
Lead sponsor
University of California, Los Angeles
Diseases
HIV
NCT number
NCT07220278

What you commit to

  • Study type: Interventional
  • Planned participants: 800
  • From 17 Nov 2025 to the primary completion date, 1 Jul 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • pregnant women because the ART/antenatal care (ANC) programs are integrated and require additional considerations and linkages with antenatal services.

Who the study is looking for

  • 15 years of age or older
  • living with HIV;
  • initiated ART for the first time\>3-months ago (i.e., not a new initiate);
  • non-pregnant;
  • experienced Treatment Interuptions during their most recent ARTappointment (\>28 days late).

Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Partners in Hope
Coordinator of this site? Confirm its status
LilongweMalawiRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.